Three Brothers Trading, LLC v. Generex Biotechnology Corp.

District Court, S.D. New York·Decided July 31, 2019·No. 1:18-cv-11585·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK THREE BROTHERS TRADING, LLC, Petitioner, 18 Civ. 11585 (KPF) -v.- OPINION AND ORDER GENEREX BIOTECHNOLOGY CORP., Respondent. KATHERINE POLK FAILLA, District Judge: Three Brothers Trading, LLC d/b/a Alternative Execution Group (“AEXG” or “Petitioner”) and Generex Biotechnology Corporation (“Generex” or “Respondent”) participated in an arbitration proceeding, after which arbitrator Daniel F. Kolb (the “Arbitrator”) issued an award in favor of AEXG (the “Award”). AEXG then filed a petition in this Court to confirm the Award under the Federal Arbitration Act (“FAA”), 9 U.S.C. §§ 1-14, while Generex moved to vacate, modify, or remand the Award back to the Arbitrator for clarification. Pursuant to this Court’s order, the parties filed cross-motions for summary judgment reiterating their earlier requests for relief. For the reasons set forth below, Generex’s motion to remand the Award back to the Arbitrator for clarification is granted, and the parties’ cross-motions for summary judgment are denied. BACKGROUND1 A. Factual History This case arises from Generex’s alleged breach of a Memorandum of

Understanding with AEXG (the “Contract”) entered into in February 2017. (Resp. 56.1 ¶ 33). In brief, the Contract provided that AEXG would secure investors for Generex’s business and, in exchange, Generex would pay AEXG a percentage of the funds received by any investor AEXG had referred. (Id. at ¶¶ 8-9). The Contract included a “sixty-day ‘No Shop’ exclusivity provision” (the “No Shop Provision”), which barred Generex from entering “into any financing transaction other than with existing shareholders” or with investors referred by

AEXG. (Resp. 56.1 ¶¶ 14-15). The exclusivity period ran from February 8, 2017, to April 9, 2017. (Id.). If Generex breached the No Shop Provision, the Contract obligated Generex “to compensate [AEXG] as if [AEXG] had sourced the financing” itself. (Id. at ¶¶ 17-18). In that instance, Generex was required

1 The facts stated herein are drawn from Petitioner’s Local Rule 56.1 Statement of Material Facts Not in Dispute (“Pet. 56.1” (Dkt. #22)), and Respondent’s Statement of Material Facts Pursuant to Local Civil Rule 56.1 (“Resp. 56.1” (Dkt. #26)), the latter of which comprises both responses to Petitioner’s assertions of material facts not in dispute and material facts ostensibly in dispute. The Opinion also draws from the final arbitration award Petitioner seeks to confirm (the “Award” (Dkt. #1-1)). Citations to the parties’ Rule 56.1 Statements incorporate by reference the documents and deposition testimony cited therein. See Local Rule 56.1(d). Generally speaking, where facts stated in a party’s Local Rule 56.1 Statement are supported by testimonial or documentary evidence, and denied with only a conclusory statement by the other party, the Court finds such facts to be true. See Local Rule 56.1(c), (d); Biberaj v. Pritchard Indus., Inc., 859 F. Supp. 2d 549, 553 n.3 (S.D.N.Y. 2012) (“A nonmoving party’s failure to respond to a Rule 56.1 statement permits the court to conclude that the facts asserted in the statement are uncontested and admissible.” (internal quotation mark omitted) (quoting T.Y. v. N.Y.C. Dep’t of Educ., 584 F.3d 412, 418 (2d Cir. 2009))). to pay AEXG damages, to include warrants for Generex stock in an amount “determined based on the amount of financing [Generex] received.” (Id. at ¶¶ 17-21). The Contract also required the parties to resolve any disputes

through arbitration. (Id. at ¶¶ 23, 24). In March 2017, Generex allegedly breached the Contract by entering into a financial transaction with a party not referred to them by AEXG. (Resp. 56.1 ¶¶ 30-33). In consequence, on November 27, 2017, AEXG sent a Demand for Arbitration Letter to Generex, demanding that the parties submit their dispute to arbitration before the American Arbitration Association (the “AAA”). (Id. at ¶ 36). The AAA’s International Centre for Dispute Resolution managed the arbitration proceedings, and the parties agreed that arbitrator Daniel F. Kolb

would preside over the case. (Resp. 56.1 ¶¶ 39-40). An arbitration hearing was held on September 24, 2018 (the “Hearing”). (Id. at ¶ 47). A few weeks after the Hearing, Generex announced that the company would issue a Stock Dividend (the “Dividend”). (Resp. 56.1 ¶ 52). The Dividend would result in the issuance of twenty shares of common stock for every one share of either issued or outstanding common stock. (Id.). The announcement included a statement explaining that any “options, warrants, and convertible securities” would be “proportionally adjusted to reflect the

dividend.” (Id. at ¶¶ 53-54). Generex did not include a price floor that options, warrants, or convertible securities had to be “at or above” in order to “receive the benefit of the proportional adjustment” of the Dividend. (Id. at ¶ 55). On November 14, 2018, Generex announced that the “record date to participate in the Stock Dividend was extended to November 20, 2018 and the dividend payment date was set for Friday, November 30, 2018.” (Resp. 56.1

¶ 59). The stock market reflected the Dividend for the first time on December 3, 2018. (Id. at ¶ 79). Since the Dividend announcement occurred after September 24, 2018, the parties were unable to introduce arguments at the Hearing concerning how the Dividend might impact the value of stock warrants owed to AEXG. (Resp. 56.1 ¶ 62). Instead, on November 2, 2018, AEXG submitted a letter to the Arbitrator that included Generex’s announcements about the Dividend. (Id. at ¶¶ 63-64, 66). AEXG requested that the Arbitrator take the Dividend into

account when determining the amount of warrants to issue in the Award. (Id.). It reasoned that had Generex not breached the Contract, AEXG would have been able to participate in the Dividend, and thus that the Award should account for the Dividend. (Id. at ¶ 67). Generex also submitted documents regarding the Dividend to the Arbitrator. (Id. at ¶ 68). Unsurprisingly, Generex opposed AEXG’s position that any warrants owed should be increased according to the terms of the Dividend. (Id. at ¶¶ 69-70). On December 3, 2018, the Arbitrator issued the Award. (Resp. 56.1

Free access — add to your briefcase to read the full text and ask questions with AI

Three Brothers Trading, LLC v. Generex Biotechnology Corp., (S.D.N.Y. 2019).

Three Brothers Trading, LLC v. Generex Biotechnology Corp. (Three Brothers Trading, LLC v. Generex Biotechnology Corp.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Rich v. Spartis
516 F.3d 75 (Second Circuit, 2008)
Brown v. Witco Corporation
340 F.3d 209 (Fifth Circuit, 2003)
Florasynth, Inc. v. Alfred Pickholz
750 F.2d 171 (Second Circuit, 1984)
Ottley v. Schwartzberg
819 F.2d 373 (Second Circuit, 1987)
William H. Hyle, Jr. v. Doctor's Associates, Inc.
198 F.3d 368 (Second Circuit, 1999)
Fischer v. CGA Computer Associates, Inc.
612 F. Supp. 1038 (S.D. New York, 1985)
LLT International Inc. v. MCI Telecommunications Corp.
69 F. Supp. 2d 510 (S.D. New York, 1999)
D.H. Blair & Co. v. Gottdiener
462 F.3d 95 (Second Circuit, 2006)
Gen. Re Life Corp. v. Lincoln Nat'l Life Ins. Co.
909 F.3d 544 (Second Circuit, 2018)
Biberaj v. Pritchard Industries, Inc.
859 F. Supp. 2d 549 (S.D. New York, 2012)